ReNeuron Group plc Block Listing Review and TVR (3082G)
01 March 2018 - 6:00PM
UK Regulatory
TIDMRENE
RNS Number : 3082G
ReNeuron Group plc
01 March 2018
1 March 2018 AIM: RENE
ReNeuron Group plc
Block Listing Review and Total Voting Rights
ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based
global leader in the development of cell-based therapeutics,
provides the following update in accordance with Schedule Six of
the AIM Rules for Companies regarding its existing block listing
arrangements.
Name: ReNeuron Group plc
---------------------------- ------------------------
Name of Scheme: ReNeuron Share Option
Schemes
---------------------------- ------------------------
Period of Return: From 1 September 2017
to 28 February 2018
---------------------------- ------------------------
Balance of unallotted 902,825 Ordinary Shares
securities under scheme(s) (of 1p each)
from previous return:
---------------------------- ------------------------
Plus: The amount by N/A
which the block scheme(s)
has been increased
since the date of
the last Review (if
any increase has been
applied for):
---------------------------- ------------------------
Less: Number of securities
issued/allotted under N/A
scheme(s) during period
---------------------------- ------------------------
Equals: Balance under 902,825 Ordinary Shares
scheme(s) not yet
issued/allotted at
end of period:
---------------------------- ------------------------
Number and class of 20,000 ordinary shares
securities originally on 13 May 2010(1)
admitted and the date
of admission:
---------------------------- ------------------------
(1) The original number and class of securities originally
admitted on 13 May 2010 was 2,000,000 ordinary shares. Following
the Reorganisation the Company has revised this disclosure to
20,000 Ordinary Shares and, where appropriate, will use this number
within the Company's Block Listing Review disclosure going
forwards.
Share Capital Consolidation
As previously announced, the Company has undertaken a 1 for 100
share capital consolidation (the "Reorganisation"), in the
six-month period since the Company's last block listing update of 1
September 2017. Immediately prior to the Reorganisation the Company
had 90,282,511 unallotted shares under its original block-listing
scheme. Following the Reorganisation an application was made to the
London Stock Exchange plc, for the admission to trading on AIM, of
a replacement block listing of 902,825 new ordinary shares of 1p
each in the capital of the Company ("Ordinary Shares"). As a result
of the Reorganisation and the replacement block admission there are
now 902,825 unallotted Ordinary Shares under the Scheme.
Total Voting Rights
The Company has 31,646,186 Ordinary Shares in issue, all with
voting rights. The Company holds no Ordinary Shares in treasury.
The figure of 31,646,186 Ordinary Shares may be used by
shareholders as the denominator for the calculation by which they
will determine if they are required to notify their interest in, or
a change in their interest in, the Company under the FCA's
Disclosure and Transparency Rules.
ENDS
ENQUIRIES:
ReNeuron +44 (0)20 3819 8400
Olav Hellebø , Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan +44 (0) 20 7466 5000
Mark Court, Sophie Wills, Stephanie Watson
Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
Nplus1 Singer Advisory LLP +44 (0) 20 7496 3000
Mark Taylor (Joint Broker)
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development
company. Based in the UK, its primary objective is the development
of novel cell-based therapies targeting areas of significant unmet
or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop
cell-based therapies for significant disease conditions where the
cells can be readily administered "off-the-shelf" to any eligible
patient without the need for additional immunosuppressive drug
treatments. The Company has therapeutic candidates in clinical
development for disability as a result of stroke and for the
blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential new nanomedicine targeting cancer and as a
potential delivery system for drugs that would otherwise be unable
to reach their site of action.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. Further information on ReNeuron and its products can
be found at www.reneuron.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBRGDDISDBGII
(END) Dow Jones Newswires
March 01, 2018 02:00 ET (07:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024